1.
Effects of vitamin D treatment on thyroid function and autoimmunity markers in patients with Hashimoto's thyroiditis-A meta-analysis of randomized controlled trials.
Jiang, H, Chen, X, Qian, X, Shao, S
Journal of clinical pharmacy and therapeutics. 2022;47(6):767-775
-
-
-
Free full text
-
Plain language summary
Hashimoto's thyroiditis (HT), also called chronic lymphocytic thyroiditis, is the most prevalent organ-specific autoimmune disorder as well as the most common cause of thyroid hypofunction. The main purpose of HT treatment is the control of hypothyroidism, including oral administration of a synthetic hormone to achieve normal circulating thyrotropin levels. The aim of this study was to review the association between vitamin D treatment in patients with HT by assessing patients’ serum circulating 25-hydroxyvitamin D - 25(OH)D - level to evaluate whether a change occurs in the course of disease. This study is a systematic review and meta-analysis of seven cohorts of patients from six studies (3 prospective cohort studies and 3 randomised controlled trials). Results show that vitamin D might significantly increase the serum 25(OH)D levels and produce changes in thyroid peroxidase antibodies titres. However, there wasn't a significant association between serum vitamin D supplementation and the levels of thyroid-stimulating hormone, thyroglobulin antibodies, free triiodothyronine and free thyroxine. Authors conclude that their findings suggest that vitamin D is not associated with the function of the thyroid in patients with HT. Thus, further well-designed randomised controlled trials with sufficient sample sizes investigating the effect of vitamin D on thyroid function are still warranted.
Abstract
INTRODUCTION Recent evidence suggested that vitamin D deficiency was associated with Hashimoto's thyroiditis (HT) pathogenesis and thyroid hypofunction. This study aimed to investigate whether vitamin D supplementation would be effective in the prevention and progression of hypothyroidism in patients with HT. METHODS PubMed, Embase and the Cochrane library were searched for randomized controlled trials (RCTs) and prospective cohort studies published from inception to August 2021. RESULTS A total of 7 cohorts of patients from six clinical trials with 258 patients with HT were included. Significant difference was found (WMD = 19.00, 95% CI: 12.43, 25.58, p < 0.001; I2 = 90.0%, pheterogeneity < 0.001) between the vitamin D group and control group in serum 25-hydroxyvitamin D level. And the combined results indicated vitamin D supplementation significantly reduced the level of thyroid peroxidase antibodies (TPO-Ab) compared to the control group (WMD = -158.18, 95% CI: -301.92, -14.45, p = 0.031; I2 = 68.8%, pheterogeneity = 0.007). Whereas no significant differences were found on the levels of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4) compared to the control group (p > 0.05). WHAT IS NEW AND CONCLUSION Our study demonstrated that vitamin D treatment might significantly increase the serum 25(OH)D levels and produce changes in TPO-Ab titres. No significant association was found between serum vitamin D treatment and the levels of TG-Ab, TSH, FT3 and FT4, suggesting that vitamin D is not associated with the function of the thyroid in patients with HT.
2.
Effects of Vitamin D Supplementation During Pregnancy on Birth Size: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Maugeri, A, Barchitta, M, Blanco, I, Agodi, A
Nutrients. 2019;11(2)
-
-
-
Free full text
Plain language summary
Vitamin D deficiency may affect mother and neonatal outcomes, increasing the risk of pregnancy complications, preterm birth, low birth weight (LBW), small for gestational age (SGA), and poor offspring health. This systematic review and meta-analysis evaluates the effects of oral vitamin D supplementation during pregnancy on foetal growth and incidence of LBW and SGA births. 13 randomised controlled trials (RCTs), published between 1980 and 2016, were included in the meta-analysis, including in total 2016 newborns (1184 from mothers in the intervention groups and 832 from controls). Dosages ranged from 200-4000 IU for daily intakes and 35000 IU to 600000 IU for single or intermittent administration. Whilst there was no evidence for publication bias (e.g. an over-reporting of positive outcomes), overall, the quality of the reviewed studies varied from very low (head circumference) to moderate (birth weight, birth length, LBW, and SGA). All studies evaluating the effect of vitamin D supplementation on blood 25-hydroxyvitamin D (OHD) levels showed that intervention significantly increased 25-OHD concentration in both mothers and infants. The meta-analysis showed that vitamin D supplementation significantly increased birth weight and length, independent of dosage and whether vitamin D was administered daily or in single/intermittent high dosages. Head circumference was increased in a non-dose dependent way with daily but not with single/intermittent vitamin D supplementation. Effects on all three parameters were seen when vitamin D was supplemented alone, but not in combination with other nutrients. Both, risk of LBW and SGA, were also significantly reduced with vitamin D supplementation.
Abstract
During pregnancy, vitamin D supplementation may be a feasible strategy to help prevent low birthweight (LBW) and small for gestational age (SGA) births. However, evidence from randomized controlled trials (RCTs) is inconclusive, probably due to heterogeneity in study design and type of intervention. A systematic literature search in the PubMed-Medline, EMBASE, and Cochrane Central Register of Controlled Trials databases was carried out to evaluate the effects of oral vitamin D supplementation during pregnancy on birthweight, birth length, head circumference, LBW, and SGA. The fixed-effects or random-effects models were used to calculate mean difference (MD), risk ratio (RR), and 95% Confidence Interval (CI). On a total of 13 RCTs, maternal vitamin D supplementation had a positive effect on birthweight (12 RCTs; MD = 103.17 g, 95% CI 62.29⁻144.04 g), length (6 RCTs; MD = 0.22 cm, 95% CI 0.11⁻0.33 cm), and head circumference (6 RCTs; MD:0.19 cm, 95% CI 0.13⁻0.24 cm). In line with these findings, we also demonstrated that maternal vitamin D supplementation reduced the risk of LBW (3 RCTs; RR = 0.40, 95% CI 0.22⁻0.74) and SGA (5 RCTS; RR = 0.69, 95% CI 0.51⁻0.92). The present systematic review and meta-analysis confirmed the well-established effect of maternal vitamin D supplementation on birth size. However, further research is required to better define risks and benefits associated with such interventions and the potential implications for public health.
3.
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.
Martineau, AR, Jolliffe, DA, Hooper, RL, Greenberg, L, Aloia, JF, Bergman, P, Dubnov-Raz, G, Esposito, S, Ganmaa, D, Ginde, AA, et al
BMJ (Clinical research ed.). 2017;356:i6583
-
-
-
Free full text
-
Plain language summary
Acute respiratory tract infections are responsible for more than 2.5 million deaths worldwide. Previous studies report consistent associations between low vitamin D levels and an increased risk of acute respiratory tract infection. Vitamin D may protect against respiratory pathogens of viral and bacterial origin, due to antimicrobial and other mechanisms. This paper is a systematic review and meta-analysis of 25 randomised double-blind placebo controlled trials of vitamin D supplementation for the prevention of acute respiratory tract infection. The trials were conducted in 14 countries in 4 continents and included a total of 11,321 participants of both sexes, aged 0-95 years. The follow-up durations ranged from seven weeks to 1.5 years. All studies administered vitamin D3 orally, using either daily or weekly doses or bolus doses 1-3 months apart, or combined daily and bolus doses. Individual participant data were obtained from 96.6% of participants. The majority of studies that were included in the analyses were considered to be of a high quality, with a low risk of bias. The analyses showed that vitamin D supplementation reduced the risk of acute respiratory tract infections among all participants. The strongest positive effects were seen in those with baseline vitamin D levels less than 25 nmol/l, when compared to those with levels higher than 25 nmol/l, although benefits were also seen in the latter. Furthermore, daily or weekly vitamin D supplementation, without additional bolus doses were shown to protect against acute respiratory tract infections, while regimens with large bolus doses did not. The authors concluded that people who are very deficient in vitamin D are most likely to benefit from daily or weekly vitamin D supplementation, without additional bolus doses, in the prevention of acute respiratory tract infections. They call for the introduction of public health measures, such as food fortification, to improve vitamin D status, particularly in settings where vitamin D deficiency is common.
Abstract
Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials.Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015.Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome.Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity <0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality.Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.Systematic review registration PROSPERO CRD42014013953.